What is the current valuation of the Europe Contract Research Organization Market?

The market valuation was 23.6 USD Billion in 2024. Read More

What is the projected market size for the Europe Contract Research Organization Market by 2035?

The market is expected to reach 44.81 USD Billion by 2035. Read More

What is the expected CAGR for the Europe Contract Research Organization Market during the forecast period 2025 - 2035?

The expected CAGR is 6.0% during the forecast period 2025 - 2035. Read More

Which service type segment is projected to have the highest valuation by 2035?

Clinical Trials is projected to reach 17.0 USD Billion by 2035. Read More

How does the Oncology segment perform in the Europe Contract Research Organization Market?

The Oncology segment was valued at 8.0 USD Billion in 2024 and is expected to grow to 15.0 USD Billion by 2035. Read More

What are the key players in the Europe Contract Research Organization Market?

Key players include IQVIA, Covance, PAREXEL International, and Charles River Laboratories. Read More

What is the projected valuation for Preclinical Services by 2035?

Preclinical Services is expected to reach 10.0 USD Billion by 2035. Read More

Which geographical region is anticipated to dominate the market by 2035?

Western Europe is projected to dominate with a valuation of 19.0 USD Billion by 2035. Read More

What is the expected growth for the Phase III study segment by 2035?

Phase III studies are expected to grow to 18.0 USD Billion by 2035. Read More

How do Academic Institutions contribute to the Europe Contract Research Organization Market?

Academic Institutions are projected to reach a valuation of 7.81 USD Billion by 2035. Read More

Europe CRO Market

ID: MRFR/HC/11110-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Europe CRO Market Research Report Information By Service Type (Early Phase Development Services, Clinical, Laboratory Service, and Others), By Application (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), By End-user (Pharmaceutical & Biotech Companies, Medical Device Companies, Academic & Research Institutes, and Others), And By Region (Germany, France, UK, Italy, Spain, and Rest of Europe) –Market Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Service Type (USD Billion)
  1. 4.1.1 Clinical Trials
  2. 4.1.2 Preclinical Services
  3. 4.1.3 Laboratory Services
  4. 4.1.4 Consulting Services
2. 4.2 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.2.1 Oncology
  2. 4.2.2 Cardiology
  3. 4.2.3 Neurology
  4. 4.2.4 Infectious Diseases
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Medical Device Companies
  4. 4.3.4 Academic Institutions
4. 4.4 Healthcare, BY Study Phase (USD Billion)
  1. 4.4.1 Phase I
  2. 4.4.2 Phase II
  3. 4.4.3 Phase III
  4. 4.4.4 Phase IV
5. 4.5 Healthcare, BY Geographical Focus (USD Billion)
  1. 4.5.1 Western Europe
  2. 4.5.2 Northern Europe
  3. 4.5.3 Southern Europe
  4. 4.5.4 Eastern Europe
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 IQVIA (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Covance (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 PAREXEL International (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Charles River Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Syneos Health (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Medpace (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 PPD (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Clinipace (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Wuxi AppTec (CN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 EUROPE MARKET ANALYSIS BY SERVICE TYPE
3. 6.3 EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
4. 6.4 EUROPE MARKET ANALYSIS BY END USER
5. 6.5 EUROPE MARKET ANALYSIS BY STUDY PHASE
6. 6.6 EUROPE MARKET ANALYSIS BY GEOGRAPHICAL FOCUS
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY END USER, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY STUDY PHASE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY STUDY PHASE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY GEOGRAPHICAL FOCUS, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY GEOGRAPHICAL FOCUS, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY SERVICE TYPE, 2026-2035 (USD Billion)
  2. 7.2.2 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2026-2035 (USD Billion)
  4. 7.2.4 BY STUDY PHASE, 2026-2035 (USD Billion)
  5. 7.2.5 BY GEOGRAPHICAL FOCUS, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Europe Healthcare Market Segmentation

Healthcare By Service Type (USD Billion, 2026-2035)

Clinical Trials
Preclinical Services
Laboratory Services
Consulting Services

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Infectious Diseases

Healthcare By End User (USD Billion, 2026-2035)

Pharmaceutical Companies
Biotechnology Companies
Medical Device Companies
Academic Institutions

Healthcare By Study Phase (USD Billion, 2026-2035)

Phase I
Phase II
Phase III
Phase IV

Healthcare By Geographical Focus (USD Billion, 2026-2035)

Western Europe
Northern Europe
Southern Europe
Eastern Europe

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”